Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
2.630
-0.060 (-2.23%)
At close: May 12, 2025, 4:00 PM
2.650
+0.020 (0.76%)
After-hours: May 12, 2025, 5:20 PM EDT
Lexeo Therapeutics Employees
Lexeo Therapeutics had 72 employees as of December 31, 2024. The number of employees increased by 14 or 24.14% compared to the previous year.
Employees
72
Change (1Y)
14
Growth (1Y)
24.14%
Revenue / Employee
n/a
Profits / Employee
-$1,518,153
Market Cap
87.31M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 72 | 14 | 24.14% |
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LXEO News
- 17 hours ago - Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights - GlobeNewsWire
- 7 days ago - Lexeo: Alignment Gained With FDA Brings Further LX2006 Program Advancement - Seeking Alpha
- 11 days ago - Lexeo Therapeutics to Present New CMC Data at the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - GlobeNewsWire
- 5 weeks ago - Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials - Benzinga
- 5 weeks ago - Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 5 months ago - Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - GlobeNewsWire